HOUSE No. 1517

The Commonwealth of Massachusetts

PRESENTED BY:

Michael S. Day

To the Honorable Senate and House of Representatives of the Commonwealth of Massachusetts in General Court assembled:

The undersigned legislators and/or citizens respectfully petition for the adoption of the accompanying bill:

An Act to enhance driver impairment prevention.

PETITION OF:

NAME:	DISTRICT/ADDRESS:	DATE ADDED:
Michael S. Day	31st Middlesex	2/2/2021
Timothy R. Whelan	1st Barnstable	2/22/2021

HOUSE No. 1517

By Mr. Day of Stoneham, a petition (accompanied by bill, House, No. 1517) of Michael S. Day and Timothy R. Whelan relative to enhanced driver impairment prevention during the incarceration and rehabilitation of drunken drivers. The Judiciary.

The Commonwealth of Alassachusetts

In the One Hundred and Ninety-Second General Court (2021-2022)

An Act to enhance driver impairment prevention.

Be it enacted by the Senate and House of Representatives in General Court assembled, and by the authority of the same, as follows:

1 Section 1. Section 24 of chapter 90 of the General Laws, as appearing in the 2014 2 Official Edition, is hereby amended by inserting, in subparagraph 4, after the words "and comply 3 with all conditions of said residential alcohol treatment program." the following language. "Such 4 person, while in the residential program, or upon intake at the counseling out-patient program, 5 shall undergo an assessment that uses a standardized evidence-based instrument performed by a 6 Bureau of Substance Addiction Services licensed provider or other licensed or certified 7 substance use disorder professional to determine whether he or she has a substance use disorder diagnosis and would likely benefit from a United States Food and Drug Administration approved 8 9 medication-assisted treatment that is indicated for the treatment of alcohol/and or other substance 10 use disorder. If a medication is indicated for such person, such person shall be seen by, or 11 referred to, a provider authorized to prescribe an FDA-approved medication, used in conjunction 12 with an individualized treatment plan, and provided for as long as clinically indicated."